Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis. Meaningful reduction in Fatigue scores seen, also stabilization of EDSS seen in all patients treated.
$TLSA #MultipleSclerosis
https://t.co/3G5XAfC557
@terracebarEFC Freebies, I don't mean ale, I mean blue wigs one week, scarves the next, blue dickie bows, blue this and that, each week first 100 people in gets a freebie or for kids only, not too costly in grand scheme of things as the footfall and atmosphere would start when doors open
The FDA give fast track designation to Foralumab (a monoclonal antibody against CD3 epsilon on t-cells) for progressive MS. There is an ongoing phase 2a trial. https://t.co/lTxOwHcZFQ